SBIR: Extremity Platform for On-demand Surgical Implantation and Tissue Integration with Osteochondral Neogenesis

OUSD (R&E) critical technology area(s): Biotechnology, Biomanufacturing

Objective: Develop an on-demand regenerative medicine platform for complete finger restoration following trauma, enabling full functional recovery and eliminating the need for traditional finger and joint repair surgeries.

Description: Joint injuries represent a critical threat to military readiness and long-term service member health. Post-traumatic osteoarthritis (PTOA) affects service members at a 12-fold higher rate than civilians, with joint injuries accounting for over 25% of all military medical evacuations from theater. Current treatment paradigms rely on joint replacement with metal and plastic implants that are fundamentally incompatible with military service requirements, preventing return to full duty and participation in high-impact activities essential for combat readiness.

The economic burden exceeds $25 billion annually when accounting for direct medical costs, lost productivity, and disability compensation. Service members with PTOA face years of progressive disability, revision surgeries, and often permanent functional limitations. Hand and finger trauma from IED blasts affect 68% of service members' ability to return to full duty, while foot and ankle injuries severely limit mobility and load-bearing capacity crucial for deployment readiness.

Current technology has demonstrated complete regeneration of 5cm segmental bone defects and full-thickness cartilage restoration in large animal models. However, effective reconstruction of dense connective tissues like tendon and ligament critical for the restoration of function has not been demonstrated. Unlike mechanical implants, regenerated tissue grows with the patient, self-repairs minor damage, and maintains the complex biomechanical properties optimized by evolution. This enables service members to return to unrestricted duty after experiencing a traumatic joint injury.

This SBIR seeks a revolutionary approach: achieving complete biological finger regeneration by converging technologies that restore native tissue architecture and function, moving beyond current methods of mechanical stabilization and repair. Proposals should detail methods to produce scaffolds that provide an anatomically precise framework for regeneration and to deliver the bioactive proteins and therapeutic factors required to promote the growth of bone, cartilage, ligaments, tendons, and the blood vessels necessary to sustain the new tissue.

The platform will be able to address finger and hand injuries critical to military function, restoring fine motor control and full range of motion to hands. Focusing on the finger joints will provide a proof-of-concept for regenerating multiple integrated tissues through tissue-engineered approaches. This smaller-scale model is advantageous because it has lower load-bearing requirements than large joint reconstructions (such as the knee, shoulder, or hip), making it an ideal initial objective.

Success metrics include complete regeneration of the finger digit verified by imaging, restoration of full range of motion and fine motor capacity appropriate. The technology will be immediately translatable to civilian populations, addressing the 1 million Americans annually who suffer major extremity injuries and establishing a new standard of care that makes prosthetics and metal implants obsolete.

Phase I

This topic is soliciting Direct to Phase II (DP2) proposals only. This project is suitable for Direct to Phase II consideration if strong preliminary data from the proposing firm demonstrates feasibility of the protein engineering platform, tendon/ligament scaffold integration approach, and 3D printing approach. DP2 justification would be based on existing proof-of-concept data showing bone and dense connective tissue regeneration, established manufacturing processes, and clear regulatory pathway through FDA Breakthrough Designation precedent.

Direct to phase II performers must demonstrate that they have previously completed the following:

• Design and fabrication of “patient-specific” scaffolds
• Conduct in vitro studies assessing cell viability, proliferation, and differentiation on scaffolds
• Perform pilot animal study to evaluate biocompatibility and early tissue regeneration
• Develop surgical protocols for scaffold implantation and tissue integration

Phase II

Objective: Complete animal studies, establish GMP manufacturing, and prepare for clinical trials.

Activities:

• Develop optimized growth factor delivery profiles for bone, ligament, tendon, cartilage, synovium, and vascular regeneration
• Conduct pivotal IDE-enabling studies in animal joint regeneration models
• Complete biocompatibility testing for all scaffold components
• Establish GMP-compliant manufacturing processes for patient-specific implants
• Develop Chemistry, Manufacturing, and Controls (CMC) documentation
• (Option) Prepare and submit Investigational Device Exemption (IDE) application to FDA

Phase II Milestones:

• Month 6: Demonstrate optimized growth factor delivery profiles for bone, ligament, tendon, cartilage, synovium, and vascular regeneration
• Month 12: Complete pivotal animal studies demonstrating safety, efficacy, and total joint regeneration
• Month 18: Establish GMP manufacturing and complete biocompatibility testing
• Month 24 (Option): Submit IDE application to FDA and receive approval

Phase III dual use applications

Commercial: Treatment of traumatic joint injuries, and congenital joint disorders in civilian populations. Market applications include orthopedic surgery, sports medicine, and trauma centers. Potential to replace current $50+ billion joint replacement industry with regenerative solutions offering superior long-term outcomes.

Department of War (DoW)/Military: Restoration of full combat readiness for service members with hand trauma, elimination of medical separations due to debilitating hand injuries, reduced long-term healthcare costs, and improved veteran quality of life. Applications span combat casualty care, training injuries, and occupational trauma across all service branches.

References

1. Belmont, P. J., Goodman, G. P., Waterman, B., DeZee, K., Burks, R., & Owens, B. D. (2013). Disease and nonbattle injuries sustained by a U.S. Army Brigade Combat Team during Operation Iraqi Freedom. Military Medicine, 178(7), 793-800.
2. Brown, T. D., Johnston, R. C., Saltzman, C. L., Marsh, J. L., & Buckwalter, J. A. (2006). Posttraumatic osteoarthritis: A first estimate of incidence, prevalence, and burden of disease. Journal of Orthopaedic Trauma, 20(10), 739-744.
3. Losina, E., Walensky, R. P., Kessler, C. L., Emrani, P. S., Reichmann, W. M., Wright, E. A., Holt, H. L., Solomon, D. H., Yelin, E., Paltiel, A. D., & Katz, J. N. (2009). Cost-effectiveness of total knee arthroplasty in the United States: Patient risk and hospital volume. Archives of Internal Medicine, 169(12), 1113-1121.
4. Moradi M, Hood B, Moradi M, Atala A. The potential role of regenerative medicine in the man-agement of traumatic patients. J Inj Violence Res. 2015 Jan;7(1):27-35. doi: 10.5249/jivr.v7i1.704. Epub 2014 Dec 13. PMID: 25618439; PMCID: PMC4288293.
5. Owens, B. D., Kragh, J. F., Wenke, J. C., Macaitis, J., Wade, C. E., & Holcomb, J. B. (2008). Combat wounds in Operation Iraqi Freedom and Operation Enduring Freedom. Journal of Trauma, 64(2), 295-299.
6. Primorac D, Molnar V, Tsoukas D, Uzieliene I, Tremolada C, Brlek P, Klaric E, Vidovic D, Zekušic M, Pachaleva J, Bernotiene E. Tissue engineering and future directions in regenerative medicine for knee cartilage repair: a comprehensive review. Croatian medical journal. 2024 Jun;65(3):268.
7. Rivera, J. C., Wenke, J. C., Buckwalter, J. A., Ficke, J. R., & Johnson, A. E. (2018). Posttraumatic osteoarthritis caused by battlefield injuries: The primary source of disability in warriors. Journal of the American Academy of Orthopaedic Surgeons, 26(7), e134-e142.
8. Spear AM, Lawton G, Staruch RM, Rickard RF. Regenerative medicine and war: a front-line focus for UK defence. NPJ Regenerative medicine. 2018 Aug 21;3(1):13.
9. Thomas, A. C., Hubbard-Turner, T., Wikstrom, E. A., & Palmieri-Smith, R. M. (2017). Epidemiology of posttraumatic osteoarthritis. Journal of Athletic Training, 52(6), 491-496.

Keywords

Regenerative medicine, joint regeneration, tissue engineering, bioactive scaffolds, military medicine, combat injuries, ligament and tendon regeneration, bone regeneration

TPOC-1-PoC

DARPA BAA Help Desk

Email

SBIR_BAA@darpa.mil